Abstract
There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast cancer. STX140, a derivative of 2-methoxyestradiol (2-MeOE2), has been shown to have excellent oral bioavailability and significantly reduces tumor growth. A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated.
Original language | English |
---|---|
Pages (from-to) | 577-81 |
Number of pages | 5 |
Journal | Anticancer research |
Volume | 28 |
Issue number | 2A |
Publication status | Published - 2008 |